Becky Taub

Becky Taub

Company: Madrigal Pharmaceuticals

Job title: Founder, Director, CEO & President


Discovering Resmetirom: A Selective Thyroid Hormone Receptor Beta Agonist in Phase 3 Clinical Development for the Treatment of NASH 1:30 pm

• Resmetirom development: The MAESTRO Phase 3 trials, multinational, double-blind, randomized, placebo-controlled clinical trial of resmetirom in patients with NASH and liver fibrosis • Outlining the challenges with NASH trials • Hearing how to create a foolproof plan to successfully recruit patients for NASH clinical trialsRead more

day: Day 1 Stream 3 PM

A NASH Drug Development Landscape Post-mortem: Critically Analyzing Lessons Learned from the Past 12 Months of NASH Drug Development Failures to Understand How to Avoid Common Mistakes & Achieve Clinical Success in 2022 & Beyond 9:30 am

• Discussing key NASH drug development updates from the past 12 months • Reflecting on recent failures in NASH drug development to discern what went wrong and understanding how to mitigate for similar faults • Setting yourself up for success: What steps must you take to maximize your chances of achieving clinical success in 2022Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.